MK-6837 has been discontinued, the company discloses.
ApexOnco Front Page
Recent articles
A US advisory committee votes against camizestrant, but does endorse a new use for Truqap.
Unlike the US FDA, the CHMP doesn't recommend approval for pre-chemo prostate cancer.
The move shows a gap developing between Relay and Lilly in PI3Kα inhibition.
The Companion-002 trial of tovecimig fails to show an overall survival benefit versus chemo.
An anti-ER “Riptac” enters phase 1.
The company drops the anti-CD19 x 4-1BB project englumafusp alfa.
The company has started a pivotal trial of its KRAS G12D inhibitor in pancreatic cancer.
